Response of 33 UK patients with infantile‐onset Pompe disease to enzyme replacement therapy
- 26 October 2015
- journal article
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 39 (2) , 261-271
Abstract
Background: Enzyme replacement therapy (ERT) for infantile‐onset Pompe disease has been commercially available for almost 10 years. We report the experience of its use in a cohort treated at three specialist lysosomal treatment centres in the UK.Methods: A retrospective case‐note review was performed, with additional data being gathered from two national audits on all such patients treated with ERT. The impact on the outcome of various characteristics, measured just prior to the initiation of ERT (baseline), was evaluated using logistic regression.Results: Thirty‐three patients were identified; 13/29 (45 %) were cross‐reactive immunological material (CRIM) negative, and nine were immunomodulated. At baseline assessment, 79 % were in heart failure, 66 % had failure to thrive and 70 % had radiological signs of focal pulmonary collapse. The overall survival rate was 60 %, ventilation‐free survival was 40 % and 30 % of patients were ambulatory. Median follow‐up of survivors was 4 years, 1.5 months (range 6 months to 13.5 years). As with previous studies, the CRIM status impacted on all outcome measures. However, in this cohort, baseline failure to thrive was related to death and lack of ambulation, and left ventricular dilatation was a risk factor for non‐ventilator‐free survival.Conclusion: The outcome of treated patients remains heterogeneous despite attempts at immunomodulation. Failure to thrive at baseline and left ventricular dilation appear to be associated with poorer outcomes.Keywords
This publication has 34 references indexed in Scilit:
- Algorithm for the Early Diagnosis and Treatment of Patients with Cross Reactive Immunologic Material-Negative Classic Infantile Pompe Disease: A Step towards Improving the Efficacy of ERTPLOS ONE, 2013
- Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapyOrphanet Journal of Rare Diseases, 2013
- Predicting cross‐reactive immunological material (CRIM) status in Pompe disease using GAA mutations: Lessons learned from 10 years of clinical laboratory testing experienceAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics, 2012
- Autophagy and mitochondria in Pompe disease: Nothing is so new as what has long been forgottenAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics, 2012
- The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: Lessons learned from infantile Pompe diseaseGenetics in Medicine, 2011
- Pompe disease: Design, methodology, and early findings from the Pompe RegistryMolecular Genetics and Metabolism, 2011
- Treatment of infantile Pompe disease with alglucosidase alpha: the UK experienceJournal of Inherited Metabolic Disease, 2010
- Early Treatment With Alglucosidase Alfa Prolongs Long-Term Survival of Infants With Pompe DiseasePediatric Research, 2009
- Age-Specific Reference Intervals for Indexed Left Ventricular Mass in ChildrenJournal of the American Society of Echocardiography, 2009
- Early administration of enzyme replacement therapy for Pompe disease: Short‐term follow‐up resultsJournal of Inherited Metabolic Disease, 2008